Current Liabilities

Accrued Manufacturing Costs

Neurocrine Biosciences Accrued Manufacturing Costs decreased by 36.6% to $81.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.1%, from $57.50M to $81.70M. Over 3 years (FY 2022 to FY 2025), Accrued Manufacturing Costs shows an upward trend with a 20.9% CAGR.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2022
Last reportedQ1 2026May 5, 2026
Metric ID: accrued_manufacturing_costs

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$72.80M$68.60M$86.20M$42.60M$59.80M$77.10M$107.50M$57.50M$84.60M$105.10M$128.80M$81.70M
QoQ Change-5.8%+25.7%-50.6%+40.4%+28.9%+39.4%-46.5%+47.1%+24.2%+22.5%-36.6%
YoY Change+18.4%+12.4%+24.7%+35.0%+41.5%+36.3%+19.8%+42.1%
Range$42.60M$128.80M
CAGR+4.3%
Avg YoY Growth+28.8%
Median YoY Growth+29.8%

Frequently Asked Questions

What is Neurocrine Biosciences's accrued manufacturing costs?
Neurocrine Biosciences (NBIX) reported accrued manufacturing costs of $81.70M in Q1 2026.
How has Neurocrine Biosciences's accrued manufacturing costs changed year-over-year?
Neurocrine Biosciences's accrued manufacturing costs increased by 42.1% year-over-year, from $57.50M to $81.70M.
What is the long-term trend for Neurocrine Biosciences's accrued manufacturing costs?
Over 3 years (2022 to 2025), Neurocrine Biosciences's accrued manufacturing costs has grown at a 20.9% compound annual growth rate (CAGR), from $72.80M to $128.80M.